Business Wire

Vidac Pharma Reports Positive Results from Phase 2a Proof-of-Concept Trial of VDA-1102 Ointment in Actinic Keratosis

Del

Vidac Pharma, a clinical-stage dermatology- and oncology-focused biopharmaceutical company, today announced positive results from a Phase 2a Proof-of-Concept (POC) clinical trial for its investigational topical drug, VDA-1102 ointment, in subjects with actinic keratosis (AK), an early form of cutaneous squamous cell carcinoma (cSCC). These results establish VDA-1102 ointment as a potential first-in-class non-irritating treatment for AK.

According to Dr. Mark Lebwohl, Professor and Chairman of Dermatology at the Icahn School of Medicine at Mount Sinai and an investigator in this trial, "the results of this trial are exciting because, until now, all the treatments we have available for actinic keratoses are irritating. We need nonirritating AK treatments that don't cause crusting and scabbing on the face."

“There is a high unmet need for an effective treatment of actinic keratoses without unpleasant skin reactions. Based on the results of this first study, VDA-1102 ointment appears to successfully go in this direction," said Professor Kristian Reich, Founder of SkinflammationTM, Hamburg, Germany.

“This proof-of-concept study established VDA-1102 ointment's safety and tolerability, demonstrating that it is completely non-irritating,” said Dr. Chaim M. Brickman, Chief Medical Officer at Vidac. “The study also confirmed VDA-1102 ointment’s efficacy in AK and paves the way for a higher dose, longer duration confirmatory Phase 2b study, which is planned for 2018.”

The randomized, double-blind, placebo-controlled, parallel-cohort Phase 2a clinical trial investigated the efficacy, safety, tolerability, and pharmacokinetics of once-daily application of topical VDA-1102 ointment for 28 days in subjects with actinic keratosis on their face or scalp (25 cm2 treatment area with 4-8 discrete Grade 1 or 2 AK lesions at baseline). Study endpoints were evaluated on Day 56. The study enrolled 93 subjects, at 8 clinical sites in the U.S. and Israel. Subjects were randomized to three treatment cohorts (5%, or 10% VDA-1102 ointment, or placebo). The mean age of the enrolled subjects was 66.5 (ranging from 37 to 93 years), and the majority of subjects (75.3%; 70 subjects) were treated for AK lesions on the face.

Safety – There were no treatment-emergent serious adverse events (AEs) or severe AEs related to the study drug. None of the subjects on the active study drug withdrew consent, discontinued treatment, or applied an emollient to the treatment field. Only 2 treatment-emergent AEs were deemed related to the study drug in the active treatment arms. Both AEs were mild and occurred in the 5% treatment group; none were reported in the 10% group. There were no clinically significant findings in vital signs, physical examinations, clinical laboratory results, or ECGs.

Tolerability – VDA-1102 ointment treatment resulted in no local skin irritation as measured by a Local Skin Reaction (LSR) score that ranges from 0 to 4 for 9 possible findings including erythema, edema, scaling, itching, and pain. On this 36-point LSR scale, the mean maximal scores for the VDA-1102 ointment treatment groups were 1.1±2.0 and 0.9±1.5 for the 5% and 10% doses, respectively, compared to 0.8±1.3 in the placebo treatment group. There was no statistical difference in the mean composite LSRs between the three treatment groups at any time (p= 0.7821).

Efficacy –The primary efficacy endpoint of the study was reduction in the total number of AK lesions (of all Grades) in the treatment field on Day 56. The 10% VDA-1102 ointment demonstrated statistically significant reduction in the total number of AK lesions vs. placebo for subjects treated on their face (p=0.023; 70 subjects), showing 50% median reduction with 10% VDA-1102 ointment (mean 38.8%±36.4%) compared to a median reduction of 20% in the placebo group (mean 29.0%±32.5%). The mean reduction in AK lesion count was greater in the 10% VDA-1102 ointment group than in the placebo group for the combined face or scalp population as well (32.1%±34.1% and 27.8%±30.6%, respectively) although the difference was not statistically significant.

The 10% VDA-1102 ointment treatment also demonstrated a statistically significant (p=0.0004) effect in an additional efficacy endpoint, reduction in the number of the more advanced lesions (only Grade 2 or 3; not counting Grade 1 lesions) for subjects treated on their face, with a median reduction of 64.6% (mean 59.9%±38.6%) compared with a median reduction of 0% in the placebo group (mean 19.9%±72.0%). This effect was even more prominent in the Per-Protocol population (N=83) where the median reduction of Grade 2 (or 3) AK lesions on the face was 80% in the 10% VDA-1102 ointment group compared to a median reduction of 0% in the placebo group. Reduction in Grade 2 (or 3) AK lesions was also statistically significant in the combined face and scalp populations (p=0.029), demonstrating a median reduction of 56.3% for the 10% VDA-1102 ointment group (mean 53.1%±41.9%) compared to a 0% median reduction in the placebo group (mean 25.9%±69.8%).

No Grade 3 lesions developed during the study in the two VDA-1102 ointment treatment groups, while 2 subjects in the placebo treated groups developed at least one Grade 3 lesion, despite having no Grade 3 lesions at baseline. A confirmatory Phase 2b study for VDA-1102 ointment in AK is planned for 2018.

About VDA-1102 ointment

VDA-1102 is a novel, potent selective modulator of the VDAC/HK2 complex in cancer cells. The drug triggers the dissociation of HK2 (hexokinase 2) from mitochondrial VDAC (voltage dependent anion channel) leading, among other effects, to apoptosis and death of the malignant cells. The selective nature of VDAC/HK2 dissociation targets only cancer cells without affecting the surrounding healthy tissue. VDA-1102 is being developed as a topical ointment for treatment of actinic keratosis (AK), cutaneous squamous cell carcinoma (cSCC), and cutaneous T-cell lymphoma (CTCL). VDA-1102 ointment has successfully completed a Phase 2a proof-of-concept study in subjects with AK, demonstrating efficacy, safety, and tolerability. VDA-1102 is also being developed as an injectable for treatment of solid tumors.

About Actinic Keratosis

Actinic keratosis (AK) is one of the most common dermatologic conditions worldwide. It affects an estimated 58 million people in the United States alone. In 2015 the global AK market was estimated at $6.6 billion. This skin disease occurs predominantly in older males with fair skin and most often begins as a rough red patch on the face, scalp, and/or extremities that may progress to a thicker, scaly, and unsightly skin lesion. AK is considered by many as an early form of cSCC. Thus, treatment is most commonly recommended by physicians in order to prevent cSCC. Current therapies are inadequate and pose significant disadvantages to public health. The limited tolerability of current treatment options greatly decreases the willingness of patients to be treated, compliant, and/or retreated. AK is a chronic disease for which patients often require repeat treatments. As a result patients with this prevalent condition elect to avoid treatment, seeking medical help only later, after their lesions have become esthetically intolerable or have advanced to malignant cSCC tumors.

About Vidac Pharma

Vidac Pharma is an innovative clinical-stage oncology- and dermatology-focused pharmaceutical company, developing novel drugs to help people suffering from a range of diseases. Vidac’s breakthrough technology targets the VDAC/HK2 system that is unique to malignant cells. The mechanism-of-action of these drugs leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue, leading to well-tolerated and efficacious treatments. Vidac is developing VDA-1102 as a topical treatment for AK and other skin malignancies, and as a parenteral drug for treatment of solid tumors. For more information regarding Vidac Pharma, please visit www.vidacpharma.com.

Contact information

Vidac Pharma
Shelly Majar, +972-2-5952090
smajar@vidacpharma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Moody’s and Reis Announce Successful Completion of Cash Tender Offer for Shares of Reis15.10.2018 10:00Pressemelding

Moody’s Corporation (NYSE:MCO) and Reis, Inc. (NASDAQ:REIS) announce today that Moody’s wholly-owned subsidiary, Moody’s Analytics Maryland Corp., successfully completed the previously announced tender offer to purchase all of the issued and outstanding shares of common stock of Reis at a purchase price of $23.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005308/en/ The tender offer expired at 11:59 p.m., New York City time, on October 12, 2018. The depositary for the tender offer has advised that as of the expiration of the tender offer, a total of 9,800,276 shares of common stock of Reis were validly tendered and not validly withdrawn in the tender offer (excluding shares with respect to which notices of guaranteed delivery were delivered) representing approximately 84.7% of Reis’s outstanding shares of common stock.

Bentley Advances Industrialization of Infrastructure Project Delivery Through ProjectWise Integration with Microsoft 36515.10.2018 09:16Pressemelding

The Year in Infrastructure 2018 Conference - Bentley Systems, Incorporated announced the general availability of integration between ProjectWise 365 Services and Microsoft 365. The collaboration capabilities of Microsoft Teams and Microsoft Flow, alongside analytics from Microsoft SharePoint and Microsoft Power BI, can now be applied to mainstream automated digital workflows within ProjectWise. The integration will enable collaborative digital workflows that transcend system boundaries throughout infrastructure capital project delivery, ensuring standards and best practices are propagated across projects, and increasing repeatability, scalability, quality, and predictability—in effect, industrializing project delivery, so that project teams can widely replicate their best projects’ successes. Neil Lee, IT Director - Applications, Mott MacDonald, said, “The integration of ProjectWise and Microsoft Office 365 will be a significant enabler for our ongoing digital strategy for project deli

Siemens and Bentley Systems Announce Integrated Asset Performance Management (APM) Solution for Power Plants15.10.2018 09:12Pressemelding

The Year in Infrastructure 2018 Conference – Siemens and Bentley Systems have announced a joint technology and service solution, consisting of their complementary offerings, to speed up the digitalization of power plants and provide intelligent analytics with a range of innovative offerings and managed services solutions. The new service, to be hosted on Siemens’ cloud-based open IoT operating system, MindSphere, will combine Bentley’s advanced asset performance software capabilities with Siemens’ complementary technology and service expertise to empower power plant owners to take full advantage of digitalization, which helps improve maintenance operations and planning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005249/en/ APM for Power Plants combines Bentley's advanced asset performance software capabilities with Siemens' industry and domain expertise. (Photo: Business Wire) Siemens’ asset performance management

Bentley Systems Acquires LEGION, Leading Pedestrian Simulation Software15.10.2018 09:09Pressemelding

The Year in Infrastructure 2018 Conference–– Bentley Systems, Incorporated, the leading global provider of comprehensive software solutions for advancing the design, construction, and operations of infrastructure, today announced the acquisition of leading pedestrian simulation software provider LEGION, based in London and supporting more than half of the world’s 40 largest transit agencies. The acquisition augments Bentley’s comprehensive modeling environment with collaborative digital workflows to explore and validate comparative simulations of pedestrian traffic scenarios. LEGION’s pedestrian simulation application offers modeling capabilities of people’s interactions with each other and physical obstacles, and activities, including circulation and evacuations, within public spaces like railway stations, airports, sports arenas, tall buildings, and street level with vehicle interactions. Using LEGION simulation tools in collaborative digital workflows with Bentley’s OpenBuildings De

Bentley Acquires Agency9 to Realize Digital Twins for Every City15.10.2018 09:07Pressemelding

The Year in Infrastructure 2018 Conference–– Bentley Systems Incorporated, the leading global provider of comprehensive software solutions for advancing the design, construction, and operations of infrastructure, today announced the acquisition of Agency9, based in Stockholm. Agency9 has already provided nearly half of Sweden’s larger municipalities with city-scale digital twin cloud services for city planning and related web-based 3D visualization. Since 2012, Agency9 has taken advantage of reality meshes created by Bentley’s ContextCapture reality modeling software as the digital context for visualizing urban infrastructure assets represented in GIS data, terrain surveys, and BIM models. Bentley’s new iTwin™ cloud services, introduced at the conference, add digital alignment and change synchronization for infrastructure engineering digital twins, and will enable OpenCities Planner (formerly Agency9 CityPlanner) to uniquely serve urban planning requirements at fuller levels of detail.

Atos and Bentley Systems Announce Strategic Partnership to Create Digital Twins for Owner-operators of Industrial and Infrastructure Assets15.10.2018 09:04Pressemelding

The Year in Infrastructure 2018 Conference – Atos, a global leader in digital transformation, and Bentley Systems, the leading global provider of comprehensive software solutions for advancing the design, construction, and operations of infrastructure, today announced a strategic partnership through which they will offer a complete solution to create and operate digital twins on behalf of industry and infrastructure asset owners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005255/en/ Atos’ global experience and expertise in digital transformation together with Bentley’s infrastructure, engineering, reality modeling and asset performance software portfolio will enable businesses to take advantage of fully-integrated and managed digital twins as a cloud-based service. This new offering will support owner-operators meet their business KPIs through the following features and benefits: Full immersive visibility of assets